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Mitochondrial disorders (MD) are multisystem diseases that may arise at any age, as a 
result of a dysfunction of the respiratory chain. The organs more frequently and 
severely affected are those that place high energetic demand like brain, skeletal 
muscle and heart. MD can be caused by mutations in the mitochondrial DNA (mtDNA) 
or in the nuclear genome (nDNA) (Wallace, 1999). In spite of the outstanding advances 
in the knowledge of the molecular basis of MD, the development of new therapies for 
these disorders is slow due in part to the lack of suitable disease models. Current 
therapies are predominantly focused on trying to alleviate symptoms, and there is an 
urgent need for the development of new therapeutic interventions. The potential of 
regenerative medicine has grown considerably in the last years since the Nobel Prize 
laureate Yamanaka reported that iPSCs could be generated from somatic cells by the 
ectopic expression of four transcription factors (Takahashi et al., 2007). iPSCs have 
major advantages including self-renewal and their capacity to differentiate into patient-
specific cell lineages (Pareja-Galeano et al., 2016). In the last 4 years, iPSCs from 
patients with MD have been generated (Fujikura et al., 2012; Cherry et al., 2013; 
Folmes et al., 2013; H€am€al€ainen et al., 2013; Galera et al., 2016; Zurita et al., 
2016; Zurita-Díaz et al., 2016). With this easily accessible source of cells, the 
possibilities are opened not only for regenerative medicine, but also for MD modeling 
and to screen potential new drugs. Regarding to this the generation of mutation-free 
iPSCs from MD patients could be an unlimited disease supply of cells for autologous 
transplantation therapy. Up to now, different strategies for achieving this are available. 
Among them, the new genome-editing techniques like the CRISPR/CAS9 system are 
very promising not only for correcting nDNA mutations but also for mutations in the 
mitochondrial genome (Jo et al., 2015). Other interesting possibilities are the 
generation of mutation free iPSCs through spontaneous segregation of heteroplasmic 
mtDNA in individual iPSCs lines or mitochondrial replacement by somatic cell nuclear 
transfer in MD caused by homoplasmic mtDNA mutations (Ma et al., 2015). However, 
an important issue remains before these iPSCs can be actually used in the clinical 
practice. This is mainly due to concerns that the epigenetic remodeling that occurs 
during the reprogramming process might originate genomic mutations that could make 
the cells tumorigenic. These concerns have led to different research studies related to 
the genomic integrity of the iPSCs but focusing only on a single type of genomic 
alteration and not considering the combined effects of single nucleotide variants 
(SNVs), copy number variations (CNVs) or structural variants. In this regard, Bhutani et 
al. (2016) assessed genome-wide mutation rates from replicate isogenic iPSC lines 
generated with the most commonly employed reprogramming methods (retrovirus, 
Sendai virus, and mRNA). Their interesting results show subtle differences in the 
number of identified variants depending on the reprogramming method and rarely 
mutations in genes associated with increased cancer risk. These data suggest that 
mutations previously reported by other groups in iPSCs are probably due to selective 
pressure that occurs when these cells are expanded in culture. In summary, based on 
the recent advances we highlight iPSCs as a promising tool for the study and 
development of new therapeutic approximations for MD. However, It should not be 
forgotten the importance of monitoring the appearance and consequences of mutations 
that can arise during the cell division and differentiation of the iPSCs. This way some of 
the concern about the theoretical chance that these transplanted cells may originate 
tumors or produce other pathologies could be more easily discarded. 
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